GlassScriptPhysician profile
Denis Matthew Mccarthy
NPI 1538121595
$17,112.85
in general payments reported to CMS, 2019-2025
13 companies · $34.87 in 2025
The $34.87 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $422 · 2021: $7,847 · 2023: $15.26 · 2024: $8,233 · 2025: $34.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,000 · Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,000.00 |
| Food and Beverage | $283.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,277.72 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,750.00 | 2021 | |
| Abbvie INC. | $346.65 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $152.53 | 2019-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.73 | 2019-2024 | Xifaxan |
| Covidien LP | $100.29 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $97.09 | 2021 | |
| Phathom Pharmaceuticals, INC. | $70.09 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $57.43 | 2024 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $38.90 | 2024 | Terlivaz |
| Madrigal Pharmaceuticals | $34.87 | 2025 | Rezdiffra |
| Ucb, INC. | $31.75 | 2019 | |
| Exelixis INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.